| Question 1: Radiopharmaceutical therapy dosimetry consists of: |
| Reference: | Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculation. New York Society of Nuclear Medicine, 1988. |
| Choice A: | Calculation of whole organ absorbed dose for prospective treatment planning and constraints on normal organ toxicity |
| Choice B: | Calculation of tumor absorbed dose for retrospective dose-response studies |
| Choice C: | Use of radiobiological, pharmacokinetic and small scale anatomical modeling |
| Choice D: | All of the above |
| Question 2: Challenges in Targeted Alpha-particle therapy dosimetry include: |
| Reference: | Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of -Particle Emitters for Targeted Radionuclide Therapy. J Nucl Med 2010;51(2):311 328 |
| Choice A: | Low count rate for SPECT or PET imaging |
| Choice B: | Short range of decay and micro-localization requiring small scale modeling |
| Choice C: | Re-localization of radioactive daughter particles in the body |
| Choice D: | Poorly known or documented radiobiological parameters |
| Choice E: | All of the above |
| Question 3: The OLINDA/EXM software is now distributed by: |
| Reference: | Huizing et al. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review EJNMMI Research (2018) 8:89 |
| Choice A: | Varian Medical Systems |
| Choice B: | Hermes Medical Solutions |
| Choice C: | Dosisoft |
| Choice D: | MIM Software Inc. |
| Question 4: Commercial voxel-level dosimetry software is primarily being used to: |
| Reference: | Kafrouni et al. Retrospective voxel-based dosimetry for assessing the body surface area model ability to predict delivered dose and radioembolization outcome J Nucl Med. (2018) 59(8):1289-1295 |
| Choice A: | Verify dose distributions from selective internal radiation therapy |
| Choice B: | Perform treatment planning calculations for selective internal radiation therapy |
| Choice C: | Verify dose distributions from systemically delivered RPT agents (e.g. Lutathera®) |
| Choice D: | Perform treatment planning calculations for systemically delivered RPT agents (e.g. Lutathera®) |
| Question 5: Which of the following is the major contributor to self absorbed dose in therapies involving Lu-177 or Y-90? |
| Reference: | Sandström M, Garske-Román U, Johansson S, Granberg D, Sundin A, Freedman N. Kidney dosimetry during (177)Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta Oncol. 2018 Apr;57(4):516-521. |
| Choice A: | Bremsstrahlung photons |
| Choice B: | Gamma-rays |
| Choice C: | Beta-particles |
| Choice D: | Both gamma-rays and beta particles contribute equally |
| Question 6: Source region time-integrated activity for post-therapy imaging based absorbed dose estimation in Y-90 microsphere radioembolization typically |
| Reference: | Elschot M, Vermolen BJ, Lam MG, de Keizer B, van den Bosch MA, de Jong HW.
Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo
yttrium-90 microsphere distribution after liver radioembolization. PLoS One.
2013;8(2):e55742. |
| Choice A: | requires Y-90 imaging at multiple time points |
| Choice B: | requires Y-90 imaging at a single time point |
| Choice C: | can be obtained by PET imaging only |
| Choice D: | cannot be determined as Y-90 has no associated gamma-rays |
